SALT LAKE CITY, UT / ACCESS Newswire / September 24, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) is offering to purchase up to 650,000 shares of its common stock at $75.00 per share. The $75.00 per share price represents a 17% premium over the average daily closing price of the stock during the last twelve months, and a 21% premium over the average daily closing price of the stock during the last twenty-four months.
The conditions of the Offer are explained in detail in the SEC Form TO Offer to Purchase and Letter of Transmittal filed with the SEC at https://www.sec.gov/Archives/edgar/data/706698/000109690626001428/0001096906-26-001428-index.html
Please read the materials carefully before making any decision with respect to the Offer. The Board of Directors of the Company has approved the tender offer but neither the Company nor the Board of Directors is making any recommendation to stockholders as to whether to tender or refrain from tendering their shares. Stockholders must make their own decisions whether or not to tender their shares and, if so, how many shares to tender.
The Letter of Transmittal and certificates for Shares and any other required documents should be sent or delivered by each stockholder or his or her broker, dealer, commercial bank, trust company or other nominee to the Depositary at its address set forth below. The Depositary for the Offer is:
Computershare Trust Company, N.A.
P.O. Box 43011
Providence, RI 02940-3100
Attn: Voluntary Corporate Actions
Additional copies of the Offer to Purchase, the Letter of Transmittal or other tender offer materials may be obtained from the Information Agent and will be furnished at the Company's expense. Questions and requests for assistance concerning the Offer should be directed to the Information Agent:
Georgeson LLC
51 West 52nd Street, 6th Floor
New York, NY 10019
Call Toll Free: (866) 920-7258
The purpose of the Offer is to provide liquidity for those stockholders desiring to sell all or a portion of their shares at a premium over the trading prices for the shares over the last two years. UTMD's first half of 2026 sales and net profits were 12% and 13% lower relative to the same period in 2025, respectively. UTMD's EBITDA for the most recent twelve months, which includes the last half of 2025 and the first half of 2026, were $15,703,744. Because of positive cash flow, UTMD believes that it can afford to make an investment that should, by antidilution, substantially enhance the value of shares held by stockholders who remain confident in the Company's future performance and do not sell at this time.